| Trial name or title |
Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo in reducing the amount of insulin (with or without metformin) needed per day, to control blood sugar, over a 24‐week period |
| Methods |
A phase III, multicenter, randomised, double‐blind, placebo‐controlled clinical trial to study the safety and insulin‐sparing efficacy of the addition of sitagliptin in ‐ Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo |
| Participants |
Participants with type 2 diabetes mellitus who have inadequate glycaemic control on insulin alone or in combination with metformin |
| Interventions |
Sitagliptin compared with placebo on the change in insulin dose in IU per day in people with type 2 diabetes mellitus (T2DM) with inadequate glycaemic control on insulin with or without metformin, who titrate insulin glargine (treat‐to‐target) |
| Outcomes |
Daily insulin dose, HbA1c, fasting plasma glucose, body weight |
| Starting date |
23 December 2011 |
| Contact information |
|
| Notes |
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc |
